Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

Magda Bahcall, Cloud P. Paweletz, Yanan Kuang, Luke J. Taus, Taebo Sim, Nam Doo Kim, Kshiti H. Dholakia, Christie J. Lau, Prafulla C. Gokhale, Pratik R. Chopade, Fangxin Hong, Zihan Wei, Jens Köhler, Paul T. Kirschmeier, Jiannan Guo, Sujuan Guo, Stephen Wang and Pasi A. Jänne

Mol Cancer Ther February 1 2022 (21) (2) 322-335; DOI: 10.1158/1535-7163.MCT-21-0344